This Article Full Text Full Text (PDF) All Versions of this Article: 92/3/887    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Blouin, J. Articles by Perreault, S. Search for Related Content PubMed PubMed Citation Articles by Blouin, J. Articles by Perreault, S. Related Collections Calcium and Bone Metabolism Female Endocrinology

Discontinuation of Antiresorptive Therapies: A Comparison between 1998–2001 and 2002–2004 among Osteoporotic Women

Faculties of Pharmacy (J.B., A.D., S.P.) and Medicine (L.-G.S.-M., J.C.F.), University of Montréal, Montréal, Québec, Canada H3C 3J7

Address all correspondence and requests for reprints to: Sylvie Perreault, Ph.D., P.O. Box 6128, Centre-Ville Station, Montréal, Québec, Canada H3C 3J7. E-mail: sylvie.perreault{at}umontreal.ca.

Context: Studies having reported high rates of discontinuation of antiresorptive therapies (ART) may not reflect their actual use.

Objectives: We compared probability of discontinuation among women aged 70 yr or older with a diagnosis of osteoporosis or recent osteoporotic fracture having started ART (alendronate, risedronate, cyclical etidronate, raloxifene, nasal calcitonin) between 1998–2001 or 2002–2004.

Patients and Methods: We constructed two cohorts of women using Régie de l’Assurance Maladie du Québec databases. Discontinuation was defined as a lapse of 30 d or longer after completion of a refill. Switching from one ART to another was allowed. Probability of discontinuation was estimated using Kaplan-Meier analysis. Multivariate Cox models were used to identify potential determinants of ART discontinuation over 1 yr.

Results: After 1 yr, probability of discontinuation was slightly lower in the 2002–2004 cohort than the 1998–2001 cohort (52.2 vs. 57.5%; P < 0.001). This difference remained significant after adjusting for determinants [adjusted rate ratio (RR) 0.92, 95% confidence interval (CI) 0.87–0.98]. Significant determinants of ART discontinuation within 1 yr included bone mineral density testing (RR 0.77; CI 0.73–0.82) performed within 2 yr prior to initiation of therapy and having consulted more than two pharmacies (RR 1.15; CI 1.06–1.25) in the year before starting therapy. In the 2002–2004 cohort, when switching was allowed, women initiating a once-weekly regimen of alendronate or risedronate did not show a 1-yr risk of discontinuation different from women initiating daily regimens of the same drugs (RR 0.90; CI 0.82–1.00).

Conclusions: Even if new dosing regimens were introduced, discontinuation of ART among osteoporotic women remains high.